AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study: Bisphosphonates don't impair skeletal uptake of Quadramet.
2002 SEP 12 - (NewsRx.com & NewsRx.net) -- Cytogen Corp. (CYTO) reported that a new study shows that the use of bisphosphonates to treat breast cancer patients with bone metastasis does not adversely affect the skeletal uptake of Quadramet, a therapeutic radiopharmaceutical used for the treatment of pain in patients with metastatic bone lesions.
The results of the study were published in the journal Clinical Nuclear Medicine (2002;27:427-430).
Bisphosphonates are compounds commonly used to inhibit the destruction of bone in cancer patients with bone metastases. The authors of the study compared the skeletal uptake of Quadramet before and 1-4 days after bisphosphonate infusion in patients with metastatic breast cancer.
The study found that bisphosphonate infusion did not interfere with the skeletal uptake of Quadramet. In addition, no difference in skeletal uptake of Quadramet was reported up to 4 weeks later in two patients.
"Quadramet is an effective treatment option in helping to relieve the pain often experienced by patients with metastatic bone cancer. We are very encouraged by these early results that indicate Quadramet can be used in conjunction with commonly prescribed bisphosphonates," said H. Joseph Reiser, PhD, president and chief executive officer of Cytogen Corp.
Once tumors have metastasized to the skeleton, they continue to grow and cause destruction of the adjacent bone. This erosion of bone stimulates new bone formation, ...
- Press Release: New study shows Quadramet treatment for bone pain continues to...
- News wire article from: Asia Africa Intelligence Wire July 24, 2002 700+ words
...does not adversely affect the skeletal uptake of Quadramet, a therapeutic radiopharmaceutical...did not interfere with the skeletal uptake of Quadramet. In addition, no difference in skeletal uptake of Quadramet was reported up to four weeks...
- Combination of QUADRAMET(R) and Novel First-in-class Proteasome Inhibitor to be...
- Press release article from: PR Newswire November 28, 2005 700+ words
...clinical trial to investigate the use of QUADRAMET(R) (samarium Sm-153 lexidronam...benefits of bortezomib in combination with QUADRAMET. (Photo: NewsCom: http://www...evaluation of the safety when combining QUADRAMET with bortezomib and may also provide...
- Cytogen Reacquires Marketing Rights to QUADRAMET(R) Pain Therapy Product.
- Press release article from: PR Newswire August 1, 2003 700+ words
...affiliate of Schering AG, Germany , to QUADRAMET(R) (Samarium Sm 153 Lexidronam...and royalties based on future sales. QUADRAMET is a skeletal targeting therapeutic radiopharmaceutical...Cytogen is very pleased to be able to offer QUADRAMET to customers through its in-house specialty...
- New Clinical Data for Cytogen's QUADRAMET and PROSTASCINT to be Reported at...
- Press release article from: Business Wire March 26, 2007 700+ words
...Data to include findings from Phase 1 QUADRAMET combination studies and outcomes data...various Phase 1 clinical results for QUADRAMET[R] (samarium Sm-153 lexidronam...from three separate Phase 1 studies of QUADRAMET in combination with docetaxel (Taxotere...
- New Data from Clinical Trials of QUADRAMET(R) in Hematological and Solid Tumor...
- Press release article from: PR Newswire June 4, 2003 700+ words
...world presented new clinical data on QUADRAMET(R) (Samarium Sm 153 Lexidronam...preliminary clinical data at ASCO regarding QUADRAMET in combination with chemotherapy demonstrating...the skeletal targeting radiotherapeutic QUADRAMET." QUADRAMET in Combination with Docetaxel...
- CYTOGEN and Berlex Laboratories Reach Exclusive Marketing Agreement For...
- Press release article from: PR Newswire October 29, 1998 700+ words
...the manufacture and sale of CYTOGEN's Quadramet(R) (Samarium Sm 153 lexidronam injection...agreement is for the marketing and sales of Quadramet in North and South America. CYTOGEN...the current contract manufacturer of Quadramet. Under the terms of the license, Berlex...
- CYTOGEN Receives FDA Clearance For Quadramet
- Press release article from: PR Newswire March 31, 1997 700+ words
...Drug Administration (FDA) to market Quadramet(TM) (Samarium Sm 153 Lexidronam Injection...with cancers that have spread to bone. Quadramet is a therapeutic agent that concentrates...bone that have been invaded with tumor. Quadramet is indicated for relief of pain in patients...
- Clinical Data Presented at ASCO Annual Meeting Demonstrates Activity of...
- Press release article from: PR Newswire May 16, 2005 700+ words
...data relating to its flagship product QUADRAMET(R) (samarium Sm-153 lexidronam...investigators who evaluated the use of high dose QUADRAMET in conjunction with chemotherapy for...another center active in studies using QUADRAMET. "While QUADRAMET is currently available...
- New Treatment for Cancer Bone Pain Receives FDA Clearance; Quadramet May Offer...
- Press release article from: PR Newswire March 31, 1997 700+ words
...Drug Administration (FDA) to market Quadramet(TM) (Samarium Sm 153 Lexidronam Injection...with cancers that have spread to bone. Quadramet was developed by CYTOGEN Corporation...by DuPont Merck Radiopharmaceuticals. Quadramet is indicated for the relief of pain in...
- Cytogen Reports Publication of Landmark Study Demonstrating Safety and Efficacy...
- Press release article from: PR Newswire May 10, 2004 700+ words
...confirms that the cancer therapy agent QUADRAMET(TM) (samarium Sm-153 lexidronam...in pain levels, patients who received QUADRAMET were able to significantly decrease their...Volume 63, No. 5, pp. 940-945). QUADRAMET offers hope to prostate, breast, multiple...
Source: HighBeam Research, Study: Bisphosphonates don't impair skeletal uptake of Quadramet.